Caribou Biosciences, Inc.

CRBUNASDAQHealthcare● Active

$1.60

$-0.07(-3.92%)

Market Cap$158193017

P/E Ratio—

52W High$3.535

52W Low$1.04

Avg Volume1.5M

Open$1.74

Beta2.33

Free Cash Flow Financials Revenue

Caribou Biosciences, Inc. (CRBU) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CRBU · free cash flow · updated Jun 15, 2026

Core FCF metrics

CRBU · FCF · TTM · margin & CAGR

Free cash flow was −$112.4M for FY2025 (fiscal year ending 2025-12-31), up 22.4% year-over-year

FY2025 Free Cash Flow−$112.4M▲ +22.4% YoY

Trailing 12M (TTM)−$101.6Mtrailing 4 quarters sum

FCF Margin< −999%−$112.4M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CRBU · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$111.0M(1M)−$112.4M▲ +22.4%—

FY2024−$138.2M(7M)−$144.7M▼ 37.9%—

FY2023−$93.3M(12M)−$104.9M▼ 7.7%-304.3%

FY2022−$91.0M(6M)−$97.4M▼ 173.3%-703.3%

FY2021−$32.5M(3M)−$35.6M▼ 3.2%-371.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CRBU · P/FCF · FCF yield · FCF per share

Caribou Biosciences, Inc. (CRBU) reported negative free cash flow of −$0.11B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CRBU · cash flow statement · operating / investing / financing

For FY2025, Caribou Biosciences, Inc. generated −$111.0M in operating cash flow and spent 1M in capital expenditures, yielding −$112.4M in free cash flow.

Operating Activities

−$111.0M

Cash from core business operations

2025-12-31

Investing Activities

+$102.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$4.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$111.0M) − |CapEx| (1M) = FCF (−$112.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CRBU vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Caribou Biosciences, Inc.YOU

CRBU

−$112.4M+22.4%-1006.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Caribou Biosciences, Inc. (CRBU) reported free cash flow of −$112.4M for FY2025 (fiscal year ending 2025-12-31), up 22.4% year-over-year.

Caribou Biosciences, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CRBU free cash flow · 8 questions

Caribou Biosciences, Inc. free cash flow was −$112.4M for FY2025, up 22.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$101.6M.

CRBU free cash flowCRBU FCFCRBU FCF 2025CRBU free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Caribou Biosciences, Inc. · Caribou Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026